Metabolomic Data Analysis with MetaboAnalyst 3.0

User ID: guest4475479668878040318

August 30, 2015

1 Data Processing and Normalization

1.1 Reading and Processing the Raw Data

MetaboAnalyst accepts a variety of data types generated in metabolomic studies, including compound concentration data, binned NMR/MS spectra data, NMR/MS peak list data, as well as MS spectra (NetCDF, mzXML, mzDATA). Users need to specify the data types when uploading their data in order for MetaboAnalyst to select the correct algorithm to process them. Table 1 summarizes the result of the data processing steps.

1.1.1 Reading Concentration Data

The concentration data should be uploaded in comma separated values (.csv) format. Samples can be in rows or columns, with class labels immediately following the sample IDs.

Samples are in columns and features in rows. The uploaded file is in comma separated values (.csv) format. The uploaded data file contains 12 (samples) by 481 (compounds) data matrix.

1.1.2 Data Integrity Check

Before data analysis, a data integrity check is performed to make sure that all the necessary information has been collected. The class labels must be present and contain only two classes. If samples are paired, the class label must be from -n/2 to -1 for one group, and 1 to n/2 for the other group (n is the sample number and must be an even number). Class labels with same absolute value are assumed to be pairs. Compound concentration or peak intensity values should all be non-negative numbers. By default, all missing values, zeros and negative values will be replaced by the half of the minimum positive value found within the data (see next section)

1.1.3 Missing value imputations

Too many zeroes or missing values will cause difficulties for downstream analysis. MetaboAnalyst offers several different methods for this purpose. The default method replaces all the missing and zero values with a small values (the half of the minimum positive values in the original data) assuming to be the detection limit. The assumption of this approach is that most missing values are caused by low abundance metabolites (i.e.below the detection limit). In addition, since zero values may cause problem for data normalization (i.e. log), they are also replaced with this small value. User can also specify other methods, such as replace by mean/median, or use K-Nearest Neighbours, Probabilistic PCA (PPCA), Bayesian PCA (BPCA) method, Singular Value Decomposition (SVD) method to impute the missing values ¹. Please choose the one that is the most appropriate for your data.

¹Stacklies W, Redestig H, Scholz M, Walther D, Selbig J. pcaMethods: a bioconductor package, providing PCA methods for incomplete data., Bioinformatics 2007 23(9):1164-1167

1.1.4 Data Filtering

The purpose of the data filtering is to identify and remove variables that are unlikely to be of use when modeling the data. No phenotype information are used in the filtering process, so the result can be used with any downstream analysis. This step can usually improves the results. Data filter is strongly recommended for datasets with large number of variables (> 250) datasets contain much noise (i.e.chemometrics data). Filtering can usually improve your results².

For data with number of variables < 250, this step will reduce 5% of variables; For variable number between 250 and 500, 10% of variables will be removed; For variable number bwteen 500 and 1000, 25% of variables will be removed; And 40% of variabled will be removed for data with over 1000 variables.

No data filtering was applied

Table 1: Summary of data processing results

	Features (positive)	Missing/Zero	Features (processed)
201	472	9	438
203	466	15	438
204	438	43	438
206	472	9	438
207	393	88	438
208	358	123	438
209	369	112	438
243	388	93	438
213	451	30	438
215	395	86	438
217	456	25	438
218	457	24	438

²Hackstadt AJ, Hess AM. Filtering for increased power for microarray data analysis, BMC Bioinformatics. 2009; 10: 11.

1.2 Data Normalization

The data is stored as a table with one sample per row and one variable (bin/peak/metabolite) per column. The normalization procedures implemented below are grouped into four categories. Sample specific normalization allows users to manually adjust concentrations based on biological inputs (i.e. volume, mass); row-wise normalization allows general-purpose adjustment for differences among samples; data transformation and scaling are two different approaches to make features more comparable. You can use one or combine both to achieve better results.

The normalization consists of the following options:

- 1. Sample specific normalization (i.e. normalize by dry weight, volume)
- 2. Row-wise procedures:
 - Normalization by the sum
 - Normalization by the sample median
 - Normalization by a reference sample (probabilistic quotient normalization)³
 - Normalization by a reference feature (i.e. creatinine, internal control)
- 3. Data transformation:
 - Generalized log transformation (glog 2)
 - Cube root transformation
- 4. Data scaling:
 - Unit scaling (mean-centered and divided by standard deviation of each variable)
 - Pareto scaling (mean-centered and divided by the square root of standard deviation of each variable)
 - Range scaling (mean-centered and divided by the value range of each variable)

Figure 1 shows the effects before and after normalization.

³Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics, 2006, Anal Chem 78 (13);4281 - 4290




Figure 1: Box plots and kernel density plots before and after normalization. The boxplots show at most 50 features due to space limit. The density plots are based on all samples. Selected methods: Row-wise normalization: Normalization to sample median; Data transformation: Log Normalization; Data scaling: Range Scaling.

2 Statistical and Machine Learning Data Analysis

MetaboAnalyst offers a variety of methods commonly used in metabolomic data analyses. They include:

- 1. Univariate analysis methods:
 - Fold Change Analysis
 - T-tests
 - Volcano Plot
 - One-way ANOVA and post-hoc analysis
 - Correlation analysis
- 2. Multivariate analysis methods:
 - Principal Component Analysis (PCA)
 - Partial Least Squares Discriminant Analysis (PLS-DA)
- 3. Robust Feature Selection Methods in microarray studies
 - Significance Analysis of Microarray (SAM)
 - Empirical Bayesian Analysis of Microarray (EBAM)
- 4. Clustering Analysis
 - Hierarchical Clustering
 - Dendrogram
 - Heatmap
 - Partitional Clustering
 - K-means Clustering
 - Self-Organizing Map (SOM)
- 5. Supervised Classification and Feature Selection methods
 - Random Forest
 - Support Vector Machine (SVM)

Please note: some advanced methods are available only for two-group sample analyais.

2.1 One-way ANOVA

Univariate analysis methods are the most common methods used for exploratory data analysis. For multigroup analysis, MetaboAnalyst provides one-way Analysis of Variance (ANOVA). As ANOVA only tells whether the overall comparison is significant or not, it is usually followed by post-hoc analyses in order to identify which two levels are different. MetaboAnalyst provides two most commonly used methods for this purpose - Fisher's least significant difference method (Fisher's LSD) and Tukey's Honestly Significant Difference (Tukey's HSD). The univariate analyses provide a preliminary overview about features that are potentially significant in discriminating the conditions under study.

Figure 2 shows the important features identified by ANOVA analysis. Table 2 shows the details of these features. The post-hoc Sig. Comparison column shows the comparisons between different levels that are significant given the p value threshold.

One-way ANOVA




Figure 2: Important features selected by ANOVA plot with p value threshold 0.05.

Table 2: Top 50 features identified by One-way ANOVA and post-hoc analysis

4 N-delta-acetylornithine 4.5143e-05 4.3454 0.0049432 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 5 sphingomyelin (d18:1/18:1, d18:2/18:0) 9.1013e-05 4.0409 0.0073321 HFD_Veh-HFD_Tx; ND_Veh-HFD_Tx; ND_Veh		Table 2: Top 50 features identified by	y One-way	ANOVA a		·
2 -lstearoyl-2-arachidonoyl-GPI (18:0/20:4) 2.9056e-05 4.4793 0.0048423 HFD_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Tx; ND_Veh_HFD_Veh_HPD_Tx; ND_V						
3 Nomostachydrine* 3,3166e-05 4,3444 Nodel-a-actylornithine 4,5143e-05 4,3444 Nodel-a-actylornithine 4,5143e-05 4,3444 Nodel-a-actylornithine 4,5143e-05 4,3444 Nodel-a-actylornithine 4,5143e-05 4,3454 Nodel-heft Nomorginine 1,0044e-04 3,0981 Nodel-heft Nomorginine 1,0044e-04 3,0981 HFD.Veh-HFD.Tr; ND.Veh-HFD.Tr; ND.Veh-HFD.Veh 16 xanthine 1,000.000000000000000000000000000000000						
4 N-delta-acetylornithine						
5 sphingomyelin (d18:1/18:1, d18:2/18:0) 9.1013e-05 4.0409 0.0073321 HFD.Veh.HFD.Tx; ND.Veh.HFD.Tx; ND.Veh 7 dehydroascorbate 1.0044e-04 3.981 0.0073321 HFD.Veh.HFD.Tx; ND.Veh.HFD.Tx; N			3.3166e-05		0.0048423	HFD_Veh-HFD_Tx; ND_Veh-HFD_Tx; ND_Veh
6 homoarginine			4.5143e-05		0.0049432	ND_Veh-HFD_Tx; ND_Veh-HFD_Veh
Control Cont		sphingomyelin (d18:1/18:1, d18:2/18:0)	9.1013e-05	4.0409	0.0073321	HFD_Veh-HFD_Tx; ND_Veh-HFD_Tx; ND_Veh
1-palmitoleoyl-3-oleoyl-glycerol (16:1/18:1)* 2-4198c-04 3.6162 0.0120580 ND_Veh_HFD_Veh HPD_Tex ND_Veh_HFD_Veh dergothioneine 2.7871c-04 3.5247 0.0120580 HFD_Veh_HFD_Tex ND_Veh_HFD_Tex ND_Veh_HFD_Veh ND_Veh_HFD_Tex ND_Veh_HFD_Veh ND_Veh_HFD_Veh ND_Veh_HFD_Tex ND_Veh_HFD_Veh ND_Veh_HFD_V						
9 decanoylcarnitine 2.9871e-04 3.5594 0.0120580 HFD_Veh_HFD_Tx ND_Veh_HFD_Tx ND_Veh_HFD_Veh			2.1636e-04		0.0120580	HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh
10 ergothíoneine			2.4198e-04		0.0120580	ND_Veh-HFD_Tx; ND_Veh-HFD_Veh
11 2-hydroxybutyrylcarnitine (1) 3.1800e-04 3.4976 0.0120580 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh			2.7583e-04			
22 cytidine						
apha-tocopherol sphingomyelin (d18:1/20:1, d18:2/20:0)* 5.5401-c04 3.2665 0.0169860 HFD.Veh.HFD.Tx; ND.Veh.HFD.Veh pyridoxal 6.0236e-04 3.2201 0.0169860 HFD.Veh.HFD.Tx; ND.Veh.HFD.Veh d16 xanthine sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)* 6.5829e-04 3.1826 0.0169860 HFD.Veh.HFD.Tx; ND.Veh.HFD.Veh HFD.Veh HFD.Veh.HFD.Tx; ND.Veh.HFD.Veh HPD.Veh.HFD.Tx; ND.Veh.HFD.Veh HPD.Veh						
14 sphingomyelin (d18:1/20:1, d18:2/20:0)* 5.5401e-04 3.2565 0.0169860 HFD.Veh.HFD.Tx; ND.Veh.HFD.Veh		v	3.5279e-04	3.4525	0.0120580	HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh
15		alpha-tocopherol	3.5788e-04		0.0120580	ND_Veh-HFD_Tx; ND_Veh-HFD_Veh
16 xanthine 6.5676-04 3.1826 0.0169860 HFD.Veh-HFD.Tx; ND.Veh-HFD.Veh 18 3-phosphoglycerate 7.4280e-04 3.1829 0.0169860 HFD.Veh-HFD.Tx; ND.Veh-HFD.Veh 19 gamma-carboxyglutamate 7.5787e-04 3.1204 0.0173140 HFD.Veh-HFD.Tx; ND.Veh-HFD.Veh 19 gamma-carboxyglutamate 7.5787e-04 3.1204 0.0173140 HFD.Veh-HFD.Tx; ND.Veh-HFD.Veh 19 dilydoxyphenylalanine (L-DOPA) 9.3512e-04 3.0226 0.0173140 HFD.Veh-HFD.Tx; ND.Veh-HFD.Veh 19 0.0173240 HFD		sphingomyelin (d18:1/20:1, d18:2/20:0)*	5.5401e-04		0.0169860	HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh
17 sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)*			6.0236e-04	3.2201	0.0169860	HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh
3-phosphoglycerate 7.4280e-04 3.1291 0.0173140 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh			6.5676e-04			HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh
gamma-carboxyglutamate			6.5929e-04			
Stachydrine			7.4280e-04		0.0173140	HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh
21						
2-hydroxybutyrate/2-hydroxyisobutyrate 9.4926e-04 3.0226 0.0179240 ND.Veh.HFD.Tx; ND.Veh.HFD.Veh			7.9060e-04		0.0173140	ND_Veh-HFD_Tx; ND_Veh-HFD_Veh
23 sebacate (decanedioate) 1.0080e-03 2.9965 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 24 phosphoenolpyruvate (PEP) 1.0697e-03 2.9707 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 25 2-methylcitrate/homocitrate 1.0743e-03 2.9689 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 26 1-(1-enyl-palmitoyl)-2-palmitoyl-2-palmitoyl-GPC (P-16:0/16:0)* 1.2087e-03 2.9177 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) 1.2087e-03 2.9177 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 29 uridine 1.2529e-03 2.9021 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 30 imidazole lactate 1.2674e-03 2.8971 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 31 heme 1.2696e-03 2.8963 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 32 stearoyl sphingomyelin (d18:1/18:0) 1.3695e-03 2.8863 0.0187240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 33 isocitrate 1.3699e-03 2.8663 0.0185140 HFD_Veh-HFD_Tx; ND						
24						,
25						
1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* 1.1034e-03 2.9573 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh						
27 1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) 1.2087e-03 2.9177 0.0179240 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 28 hypoxanthine 1.2142e-03 2.9157 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 30 imidazole lactate 1.2674e-03 2.8971 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 31 heme 1.2696e-03 2.8963 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 32 stearoyl sphingomyelin (d18:1/18:0) 1.3095e-03 2.8892 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 33 isocitrate 1.3692e-03 2.8635 0.0181740 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 34 1-palmitoleoyl-2-oleoyl-glycerol (16:1/18:1)* 1.4275e-03 2.8454 0.0183900 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 35 1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) 1.4843e-03 2.8285 0.0185410 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 36 retinol (Vitamin A) 1.5812e-03 2.8010 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 37 gamma-aminobutyrate (GABA) 1.6015e-03 2.7955 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 38 uridine 5'-monophosphate (UMP) 1.6589e-03 2.7802 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 42 hexadecanedioate 1.8121e-03 2.7418 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7016 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 48 0-sulfo-L-tyrosine 2.0319e-03 2.6743 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Ve						
28						
29 uridine 1.2529e-03 2.9021 0.0179240 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 30 imidazole lactate 1.2674e-03 2.8961 0.0179240 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 31 heme 1.2696e-03 2.8963 0.0179240 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 32 stearoyl sphingomyelin (d18:1/18:0) 32 stearoyl sphingomyelin (d18:1/18:0) 33 isocitrate 1.3692e-03 2.8635 0.0181740 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 34 1-palmitoleoyl-2-oleoyl-glycerol (16:1/18:1)* 1.4275e-03 2.8454 0.0183900 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 35 1-stearoyl-2-arachidonoyl-GFS (18:0/20:4) 1.4843e-03 2.8285 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 36 retinol (Vitamin A) 1.5812e-03 2.8010 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 37 gamma-aminobutyrate (GABA) 1.6015e-03 2.7955 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 38 uridine 5'-monophosphate (UMP) 1.6889e-03 2.7802 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 42 hexadecanedioate 43 N-acetylglycine 44 adenosine 5'-monophosphate (AMP) 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 46 arachidonoyl ethanolamide 47 3-hydroxyisobutyrate 48 O-sulfo-L-tyrosine 49 tetradecanedioate 40 -sulfo-L-tyrosine 40 -sulfo-L-tyrosine 41 -sulfo-data (2.6743 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 tetradecanedioate 46 -sulfo-L-tyrosine 47 3-hydroxyisobutyrate 48 O-sulfo-L-tyrosine 49 tetradecanedioate 40 -sulfo-L-tyrosine 40 -sulfo-L-tyrosine 41 -sulfo-data (2.6743 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 tetradecanedioate 46 -sulfo-L-tyrosine 47 3-hydroxyisobutyrate 48 O-sulfo-L-tyrosine 49 1-sulfo-data (2.6743 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 40 -sulfo-L-tyrosine 41 -sulfo-L-tyrosine 42 -sulfo-L-tyrosine 43 -sulfo-L-tyrosine 44 -sulfo-L-tyrosine 45 -sulfo-L-tyrosine 46 -sulfo-L-tyrosine 47 -sulfo-L-tyrosine 48 -sulfo-L-tyrosine 49 -sulfo-L-tyrosine 49 -sulfo-L-tyrosine 49 -sulfo-L-tyrosine 49 -sulfo-L-tyrosine 49 -sulfo-L-tyrosine 49 -sulfo-L-tyrosine 40 -sulfo-L-tyrosine 41 -sulfo-L-tyrosine 4						,
30						
31 heme 1.2696e-03 2.8963 0.0179240 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 32 stearoyl sphingomyelin (d18:1/18:0) 1.3095e-03 2.8829 0.0179240 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 33 isocitrate 1.3692e-03 2.8635 0.0181740 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 34 1-palmitoleoyl-2-oleoyl-glycerol (16:1/18:1)* 1.4275e-03 2.8454 0.0183900 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 35 1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) 1.4843e-03 2.8285 0.0185410 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 36 retinol (Vitamin A) 1.5812e-03 2.8010 0.0185410 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 37 gamma-aminobutyrate (GABA) 1.6015e-03 2.7955 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 38 uridine 5'-monophosphate (UMP) 1.6589e-03 2.7802 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410						
32 stearoyl sphingomyelin (d18:1/18:0) 1.3095e-03 2.8829 0.0179240 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 33 isocitrate 1.3692e-03 2.8635 0.0181740 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 34 1-palmitoleoyl-2-oleoyl-glycerol (16:1/18:1)* 1.4275e-03 2.8454 0.0183900 ND_Veh_HFD_Veh 35 1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) 1.4843e-03 2.8285 0.0185410 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 36 retinol (Vitamin A) 1.5812e-03 2.8010 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 37 gamma-aminobutyrate (GABA) 1.6015e-03 2.7955 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 39 16-hydroxypalmitate 1.6816e-03 2.7743 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7315 0.0185410 HF						
33 isocitrate 1.3692e-03 2.8635 0.0181740 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 34 1-palmitoleoyl-2-oleoyl-glycerol (16:1/18:1)* 1.4275e-03 2.8454 0.0183900 ND_Veh_HFD_Veh 35 1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) 1.4843e-03 2.8285 0.0185410 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 36 retinol (Vitamin A) 1.5812e-03 2.8010 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 37 gamma-aminobutyrate (GABA) 1.6015e-03 2.7955 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 38 uridine 5'-monophosphate (UMP) 1.6589e-03 2.7802 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 39 16-hydroxypalmitate 1.6816e-03 2.7743 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 ND_Veh_HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 ND_Veh_HFD_Veh 42 hexadecanedioate 1.8121e-03 2.7519 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh_HFD_Veh						*
34 1-palmitoleoyl-2-oleoyl-glycerol (16:1/18:1)* 1.4275e-03 2.8454 0.0183900 ND_Veh-HFD_Veh 35 1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) 1.4843e-03 2.8285 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 36 retinol (Vitamin A) 1.5812e-03 2.8010 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 37 gamma-aminobutyrate (GABA) 1.6015e-03 2.7955 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 38 uridine 5'-monophosphate (UMP) 1.6589e-03 2.7802 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 ND_Veh-HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 42 hexadecanedioate 1.8121e-03 2.7418 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoy						
35 1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) 1.4843e-03 2.8285 0.0185410 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 36 retinol (Vitamin A) 1.5812e-03 2.8010 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 37 gamma-aminobutyrate (GABA) 1.6015e-03 2.7955 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 38 uridine 5'-monophosphate (UMP) 1.6589e-03 2.7802 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 49 16-hydroxypalmitate 1.6816e-03 2.7743 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 ND_Veh_HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 ND_Veh_HFD_Veh 42 hexadecanedioate 1.812le-03 2.7418 0.0185410 ND_Veh_HFD_Tx; ND_Veh_HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Ve						
36 retinol (Vitamin A) 1.5812e-03 2.8010 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 37 gamma-aminobutyrate (GABA) 1.6015e-03 2.7955 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 38 uridine 5'-monophosphate (UMP) 1.6589e-03 2.7802 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 39 16-hydroxypalmitate 1.6816e-03 2.7743 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 42 hexadecanedioate 1.8121e-03 2.7418 0.0185410 ND_Veh-HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HF						
37 gamma-aminobutyrate (GABA) 1.6015e-03 2.7955 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 38 uridine 5'-monophosphate (UMP) 1.6589e-03 2.7802 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 39 16-hydroxypalmitate 1.6816e-03 2.7743 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 42 hexadecanedioate 1.8121e-03 2.7418 0.0185410 ND_Veh-HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine						
38 uridine 5'-monophosphate (UMP) 1.6589e-03 2.7802 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 39 16-hydroxypalmitate 1.6816e-03 2.7743 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 ND_Veh-HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 42 hexadecanedioate 1.8121e-03 2.7418 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 47 3-hydroxyisobutyrate 2.0319e-03 2.6955 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine		retinol (Vitamin A)				
39 16-hydroxypalmitate 1.6816e-03 2.7743 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 ND_Veh-HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 42 hexadecanedioate 1.8121e-03 2.7418 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 2.1171e						
40 myristoleate (14:1n5) 1.7282e-03 2.7624 0.0185410 ND_Veh-HFD_Veh 41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 42 hexadecanedioate 1.8121e-03 2.7418 0.0185410 ND_Veh-HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh-HFD_Veh						*
41 1-palmitoyl-2-oleoyl-GPG (16:0/18:1) 1.7705e-03 2.7519 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 42 hexadecanedioate 1.8121e-03 2.7418 0.0185410 ND_Veh-HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh-HFD_Veh						
42 hexadecanedioate 1.8121e-03 2.7418 0.0185410 ND_Veh-HFD_Veh 43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh-HFD_Veh						
43 N-acetylglycine 1.8388e-03 2.7355 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 44 adenosine 5'-monophosphate (AMP) 1.9192e-03 2.7169 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh-HFD_Veh						
44 adenosine 5'-monophosphate (AMP) 45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh_HFD_Tx; ND_Veh_HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh_HFD_Veh						
45 1-(1-enyl-palmitoyl)-2-linoleoyl-GPĆ (P-16:0/18:2)* 1.9243e-03 2.7157 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh						
46 arachidonoyl ethanolamide 1.9881e-03 2.7016 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh-HFD_Veh		adenosine 5'-monophosphate (AMP)				· · · · · · · · · · · · · · · · · · ·
47 3-hydroxyisobutyrate 2.0161e-03 2.6955 0.0185410 ND_Veh-HFD_Tx; ND_Veh-HFD_Veh 48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh-HFD_Veh		1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)*				
48 O-sulfo-L-tyrosine 2.0319e-03 2.6921 0.0185410 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh 49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh-HFD_Veh						
49 tetradecanedioate 2.1171e-03 2.6743 0.0189250 ND_Veh-HFD_Veh						
50 myristate (14:0) 2.2057e-03 2.6565 0.0193220 HFD_Veh-HFD_Tx; ND_Veh-HFD_Veh						
	50	myristate (14:0)	2.2057e-03	2.6565	0.0193220	HFD_ven-HFD_Tx; ND_ven-HFD_Veh

2.2 Correlation Analysis

Correlation analysis can be used to visualize the overall correlations between different features It can also be used to identify which features are correlated with a feature of interest. Correlation analysis can also be used to identify if certain features show particular patterns under different conditions. Users first need to define a pattern in the form of a series of hyphenated numbers. For example, in a time-series study with four time points, a pattern of of 1–2–3–4 is used to search compounds with increasing the concentration as time changes; while a pattern of 3–2–1–3 can be used to search compounds that decrease at first, then bounce back to the original level.

Figure 3 shows the overall correlation heatmap.

Figure 3: Correlation Heatmaps

2.3 Principal Component Analysis (PCA)

PCA is an unsupervised method aiming to find the directions that best explain the variance in a data set (X) without referring to class labels (Y). The data are summarized into much fewer variables called *scores* which are weighted average of the original variables. The weighting profiles are called *loadings*. The PCA analysis is performed using the prcomp package. The calculation is based on singular value decomposition.

The Rscript chemometrics.R is required. Figure 4 is pairwise score plots providing an overview of the various seperation patterns among the most significant PCs; Figure 5 is the scree plot showing the variances explained by the selected PCs; Figure 6 shows the 2-D scores plot between selected PCs; Figure 7 shows the 3-D scores plot between selected PCs; Figure 8 shows the loadings plot between the selected PCs; Figure 9 shows the biplot between the selected PCs.




Figure 4: Pairwise score plots between the selected PCs. The explained variance of each PC is shown in the corresponding diagonal cell.




Figure 5: Scree plot shows the variance explained by PCs. The green line on top shows the accumulated variance explained; the blue line underneath shows the variance explained by individual PC.




Figure 6: Scores plot between the selected PCs. The explained variances are shown in brackets.

Figure 7: 3D score plot between the selected PCs. The explained variances are shown in brackets.




Figure 8: Loadings plot for the selected PCs. $\,$




Figure 9: PCA biplot between the selected PCs. Note, you may want to test different centering and scaling normalization methods for the biplot to be displayed properly.

2.4 Partial Least Squares - Discriminant Analysis (PLS-DA)

PLS is a supervised method that uses multivariate regression techniques to extract via linear combination of original variables (X) the information that can predict the class membership (Y). The PLS regression is performed using the plsr function provided by R pls package⁴. The classification and cross-validation are performed using the corresponding wrapper function offered by the caret package⁵.

To assess the significance of class discrimination, a permutation test was performed. In each permutation, a PLS-DA model was built between the data (X) and the permuted class labels (Y) using the optimal number of components determined by cross validation for the model based on the original class assignment. MetaboAnalyst supports two types of test statistics for measuring the class discrimination. The first one is based on prediction accuracy during training. The second one is separation distance based on the ratio of the between group sum of the squares and the within group sum of squares (B/W-ratio). If the observed test statistic is part of the distribution based on the permuted class assignments, the class discrimination cannot be considered significant from a statistical point of view.⁶

There are two variable importance measures in PLS-DA. The first, Variable Importance in Projection (VIP) is a weighted sum of squares of the PLS loadings taking into account the amount of explained Y-variation in each dimension. Please note, VIP scores are calculated for each components. When more than components are used to calculate the feature importance, the average of the VIP scores are used. The other importance measure is based on the weighted sum of PLS-regression. The weights are a function of the reduction of the sums of squares across the number of PLS components. Please note, for multiple-group (more than two) analysis, the same number of predictors will be built for each group. Therefore, the coefficient of each feature will be different depending on which group you want to predict. The average of the feature coefficients are used to indicate the overall coefficient-based importance.

Figure 10 shows the overview of scores plots; Figure 11 shows the 2-D scores plot between selected components; Figure 12 shows the 3-D scores plot between selected components; Figure 13 shows the loading plot between the selected components; Figure 14 shows the classification performance with different number of components; Figure 15 shows the results of permutation test for model validation; Figure 16 shows important features identified by PLS-DA.

⁴Ron Wehrens and Bjorn-Helge Mevik. pls: Partial Least Squares Regression (PLSR) and Principal Component Regression (PCR), 2007, R package version 2.1-0

⁵Max Kuhn. Contributions from Jed Wing and Steve Weston and Andre Williams. caret: Classification and Regression Training, 2008, R package version 3.45

⁶Bijlsma et al. Large-Scale Human Metabolomics Studies: A Strategy for Data (Pre-) Processing and Validation, Anal Chem. 2006, 78 567 - 574




Figure 10: Pairwise scores plots between the selected components. The explained variance of each component is shown in the corresponding diagonal cell.



Figure 11: Scores plot between the selected PCs. The explained variances are shown in brackets.

Figure 12: 3D scores plot between the selected PCs. The explained variances are shown in brackets.




Figure 13: Loadings plot between the selected PCs.




Figure 14: PLS-DA classification using different number of components. The red circle indicates the best classifier.

Figure 15: PLS-DA model validation by permutation tests based on . The p value based on permutation is .




Figure 16: Important features identified by PLS-DA. The colored boxes on the right indicate the relative concentrations of the corresponding metabolite in each group under study.

2.5 Significance Analysis of Microarray (SAM)

SAM is a well-established statistical method for identification of differentially expressed genes in microarray data analysis. It is designed to address the false discovery rate (FDR) when running multiple tests on high-dimensional microarray data. SAM assigns a significance score to each variable based on its change relative to the standard deviation of repeated measurements. For a variable with scores greater than an adjustable threshold, its relative difference is compared to the distribution estimated by random permutations of the class labels. For each threshold, a certain proportion of the variables in the permutation set will be found to be significant by chance. The proportion is used to calculate the FDR. SAM is performed using the siggenes package⁷. Users need to specify the Delta value to control FDR in order to proceed.

Figure 17 shows the significant features identified by SAM. Table 3 shows the details of these features.

Table 3: Top 50 features identified by SAM

	1able 3: 1op 50 leatures				
	Compounds	d.value	stdev	rawp	q.value
1	4-guanidinobutanoate	4.8259	0.014954	0	0
2	N-delta-acetylornithine	4.4205	0.02084	4.5662e-05	0.0012549
3	homostachydrine*	4.2147	0.018119	6.8493e-05	0.0012549
4	homoarginine	4.1566	0.024471	9.1324e-05	0.0012549
5	sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)	3.8225	0.040334	0.00027397	0.0030117
6	alpha-tocopherol	3.6703	0.031263	0.00052511	0.0037646
7	dehydroascorbate	3.5768	0.025885	0.00068493	0.0037646
8	N-acetylmethionine	3.5627	0.058716	0.00073059	0.0037646
9	sphingomyelin (d18:1/18:1, d18:2/18:0)	3.5482	0.019843	0.00075342	0.0037646
10	gamma-carboxyglutamate	3.545	0.038518	0.00075342	0.0037646
11	stachydrine	3.5081	0.038582	0.00082192	0.0037646
12	sphingomyelin (d18:1/20:1, d18:2/20:0)*	3.4933	0.03399	0.00082192	0.0037646
13	1-stearoyl-2-arachidonoyl-GPI (18:0/20:4)	3.4112	0.013841	0.0010274	0.003986
14	imidazole lactate	3.3592	0.043255	0.0011187	0.003986
15	heme	3.3591	0.043281	0.0011187	0.003986
16	orotidine	3.349	0.058382	0.0011872	0.003986
17	hypoxanthine	3.321	0.041963	0.0012329	0.003986
18	adenosine 5'-monophosphate (AMP)	3.1952	0.047414	0.0016895	0.0042472
19	3-phosphoglycerate	3.16	0.0332	0.0018037	0.0042472
20	decanoylcarnitine	3.1311	0.023891	0.0018721	0.0042472
21	retinol (Vitamin A)	3.131	0.042909	0.0018721	0.0042472
22	cytidine	3.1276	0.025748	0.0018721	0.0042472
23	1-palmitoleoyl-3-oleoyl-glycerol (16:1/18:1)*	3.1249	0.022904	0.001895	0.0042472
24	glycerophosphoinositol*	3.1233	0.086715	0.001895	0.0042472
25	pyridoxal	3.1089	0.030353	0.0019863	0.0042472
26	guanosine 5'- monophosphate (5'-GMP)	3.0795	0.055195	0.0020091	0.0042472
27	arachidonoyl ethanolamide	3.0428	0.045103	0.0022146	0.0045082
28	trigonelline (N'-methylnicotinate)	2.999	0.050464	0.0023288	0.0045713
29	stearoyl sphingomyelin (d18:1/18:0)	2.9542	0.037225	0.0025799	0.0045881
30	uridine 5'-monophosphate (UMP)	2.9527	0.040544	0.0025799	0.0045881
31	sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1)	2.9477	0.062931	0.0026027	0.0045881
32	1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)	2.9416	0.042652	0.0026712	0.0045881
33	1-stearoyl-2-arachidonoyl-GPS (18:0/20:4)	2.9103	0.038226	0.0029909	0.0048718
34	3-hydroxybutyrylcarnitine (1)	2.9087	0.022925	0.0030137	0.0048718
35	betaine	2.8785	0.051321	0.0031735	0.0049836
36	isocitrate	2.853	0.036225	0.0034018	0.0050194
37	phosphoenolpyruvate (PEP)	2.8481	0.033148	0.0034475	0.0050194
38	1-palmitoyl-2-oleoyl-GPG (16:0/18:1)	2.8454	0.03964	0.0034703	0.0050194
39	dihydoxyphenylalanine (L-DOPA)	2.8086	0.031126	0.0036758	0.0050717
40	citrate	2.8009	0.062811	0.00379	0.0050717
41	xanthine	2.7781	0.027322	0.0039269	0.0050717
42	sebacate (decanedioate)	2.7542	0.031188	0.0041096	0.0050717
43	uridine	2.7423	0.033444	0.0041324	0.0050717
44	urate	2.7368	0.045532	0.0041324	0.0050717
45	1-methylnicotinamide	2.7291	0.064109	0.0042466	0.0050717
46	N-acetylarginine	2.7137	0.060877	0.0042400	0.0050717
47	myristate (14:0)	2.7099	0.040466	0.0043030	0.0050717
48	1-palmitoleoyl-2-oleoyl-glycerol (16:1/18:1)*	2.7087	0.034493	0.0044004	0.0050717
49	5-oxoproline	2.6783	0.068532	0.0044292	0.0050717
50	dimethylarginine (SDMA + ADMA)	2.6757	0.008332 0.047862	0.004589	0.0051198
-50	dimeniyiaigiiiiie (SDMA + ADMA)	2.0101	0.041002	0.0040010	0.0001130

 $^{^7}$ Holger Schwender. siggenes: Multiple testing using SAM and Efron's empirical Bayes approaches, 2008, R package version 1.16.0




Figure 17: Significant features identified by SAM. The green circles represent features that exceed the specified threshold.

2.6 Hierarchical Clustering

In (agglomerative) hierarchical cluster analysis, each sample begins as a separate cluster and the algorithm proceeds to combine them until all samples belong to one cluster. Two parameters need to be considered when performing hierarchical clustering. The first one is similarity measure - Euclidean distance, Pearson's correlation, Spearman's rank correlation. The other parameter is clustering algorithms, including average linkage (clustering uses the centroids of the observations), complete linkage (clustering uses the farthest pair of observations between the two groups), single linkage (clustering uses the closest pair of observations) and Ward's linkage (clustering to minimize the sum of squares of any two clusters). Heatmap is often presented as a visual aid in addition to the dendrogram.

Hierarchical clustering is performed with the hclust function in package stat. Figure 18 shows the clustering result in the form of a dendrogram. Figure 19 shows the clustering result in the form of a heatmap.




Figure 18: Clustering result shown as dendrogram (distance measure using euclidean, and clustering algorithm using ward).

2.7 Random Forest (RF)

Random Forest is a supervised learning algorithm suitable for high dimensional data analysis. It uses an ensemble of classification trees, each of which is grown by random feature selection from a bootstrap sample at each branch. Class prediction is based on the majority vote of the ensemble. RF also provides other useful information such as OOB (out-of-bag) error, variable importance measure, and outlier measures. During tree construction, about one-third of the instances are left out of the bootstrap sample. This OOB data is then used as test sample to obtain an unbiased estimate of the classification error (OOB error). Variable importance is evaluated by measuring the increase of the OOB error when it is permuted. The outlier measures are based on the proximities during tree construction.

RF analysis is performed using the randomForest package⁸. Table 4 shows the confusion matrix of random forest. Figure 20 shows the cumulative error rates of random forest analysis for given parameters. Figure 21 shows the important features ranked by random forest. Figure 22 shows the outlier measures of all samples for the given parameters. The OOB error is 0.167

Random Forest classification




Figure 20: Cumulative error rates by Random Forest classification. The overall error rate is shown as the black line; the red and green lines represent the error rates for each class.

	HFD_Tx	HFD_Veh	ND_Veh	class.error
HFD_Tx	2.00	1.00	1.00	0.50
HFD_Veh	0.00	4.00	0.00	0.00
ND_Veh	0.00	0.00	4.00	0.00

Table 4: Random Forest Classification Performance

⁸ Andy Liaw and Matthew Wiener. Classification and Regression by randomForest, 2002, R News




Figure 21: Significant features identified by Random Forest. The features are ranked by the mean decrease in classification accuracy when they are permuted.




Figure 22: Potential outliers identified by Random Forest. Only the top five are labeled.

3 Data Annotation

Please be advised that MetaboAnalyst also supports metabolomic data annotation. For NMR, MS, or GC-MS peak list data, users can perform peak identification by searching the corresponding libraries. For compound concentration data, users can perform metabolite set enrichment analysis and metabolic pathway analysis.

The report was generated on Sun Aug 30 19:27:37 2015 with R version 3.0.3 (2014-03-06). Thank you for using MetaboAnalyst! For suggestions and feedback please contact Jeff Xia (jeff.xia@mcgill.ca).